Cumberland delays release of FIGHT DMD ifetroban long-term data; no new timeline

CUMBERLAND PHARMACEUTICALS INC

Phase 2 FIGHT DMD open-label extension long-term safety/efficacy data for ifetroban not yet available.
Company no longer expects to present data in August 2026 as stated at PPMD conference on June 26, 2026.
Data was originally expected at Parent Project Muscular Dystrophy annual conference in Orlando.
Cumberland will present at a future date when data becomes available; no revised timeline given.
Ifetroban is an oral candidate for Duchenne muscular dystrophy heart disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.